<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">CdpCLX7D6nnFcZSJwT9Xw6c</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2020000300525</article-id>
      <article-id pub-id-type="publisher-id">abc.20200070</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20200070</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Minieditorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Escores Progn&#243;sticos de Mortalidade na Cirurgia Card&#237;aca para Endocardite Infecciosa</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Martins</surname>
            <given-names>Alexandre Bahia Barreiras</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-5561-999X</contrib-id>
          <name>
            <surname>Lamas</surname>
            <given-names>Cristiane da Cruz</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="orgdiv1">Unidade Cardiointensiva</institution>
        <institution content-type="orgname">Cl&#237;nica S&#227;o Vicente da G&#225;vea</institution>
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Unidade Cardiointensiva - Cl&#237;nica S&#227;o Vicente da G&#225;vea, Rio de Janeiro, RJ - Brasil</institution>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution content-type="orgdiv1">Coordena&#231;&#227;o de Ensino e Pesquisa</institution>
        <institution content-type="orgname">Instituto Nacional de Cardiologia</institution>
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Coordena&#231;&#227;o de Ensino e Pesquisa - Instituto Nacional de Cardiologia, Rio de Janeiro, RJ - Brasil</institution>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <institution content-type="orgdiv1">Escola de Ci&#234;ncias da Sa&#250;de</institution>
        <institution content-type="orgname">Universidade do Grande Rio</institution>
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Escola de Ci&#234;ncias da Sa&#250;de - Universidade do Grande Rio (Unigranrio), Rio de Janeiro, RJ - Brasil</institution>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <institution content-type="orgdiv2">Centro Hospitalar</institution>
        <institution content-type="orgdiv1">Instituto Nacional de Infectologia Evandro Chagas</institution>
        <institution content-type="orgname">Fiocruz</institution>
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Centro Hospitalar - Instituto Nacional de Infectologia Evandro Chagas - Fiocruz, Rio de Janeiro, RJ &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01"> Correspond&#234;ncia: Cristiane da Cruz Lamas &#8226; Instituto Nacional de Cardiologia - Coordena&#231;&#227;o de Ensino e Pesquisa - Rua das Laranjeiras, 374 5&#186; andar. CEP 22240-006, Rio de Janeiro, RJ &#8211; Brasil Email: <email>cristianelamas@gmail.com</email>
				</corresp>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>06</day>
        <month>04</month>
        <year>2020</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <season>May-Jun</season>
        <year>2020</year>
      </pub-date>
      <volume>114</volume>
      <issue>3</issue>
      <fpage>525</fpage>
      <lpage>529</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt">
        <kwd>Endocardite/cirurgia</kwd>
        <kwd>Mortalidade Hospitalar</kwd>
        <kwd>Cirurgia Card&#237;aca/mortalidade</kwd>
        <kwd>Progn&#243;stico</kwd>
        <kwd>Indicadores</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado do Rio de Janeiro</funding-source>
          <award-id># E26/202.782/2015</award-id>
        </award-group>
        <funding-statement>Fontes de Financiamento. Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado do Rio de Janeiro (FAPERJ; bolsa Jovem Cientista do Nosso Estado, # E26/202.782/2015).</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="6"/>
        <equation-count count="0"/>
        <ref-count count="14"/>
        <page-count count="5"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>O artigo de Pivatto F Jr et al.,<sup><xref ref-type="bibr" rid="B1">1</xref></sup> nos permite discutir a importante quest&#227;o dos escores progn&#243;sticos em pacientes submetidos &#224; cirurgia card&#237;aca para endocardite infecciosa (EI).<sup><xref ref-type="bibr" rid="B1">1</xref></sup> O manejo da EI do lado esquerdo geralmente envolve cirurgia durante a admiss&#227;o &#237;ndice, e o principal desafio &#233; identificar r&#225;pida e corretamente pacientes de alto risco e transferi-los para institui&#231;&#245;es com uma equipe cir&#250;rgica com experi&#234;ncia em cirurgia de endocardite.</p>
    <p>Os escores progn&#243;sticos s&#227;o importantes por v&#225;rias raz&#245;es: uma estimativa razo&#225;vel do risco de morte &#233; importante na tomada de decis&#227;o cl&#237;nica em rela&#231;&#227;o &#224; indica&#231;&#227;o cir&#250;rgica; a estimativa &#233; necess&#225;ria para informar os pacientes e suas fam&#237;lias sobre o risco cir&#250;rgico; a estratifica&#231;&#227;o de risco permite uma compara&#231;&#227;o razo&#225;vel dos resultados da cirurgia card&#237;aca, para que cirurgi&#245;es e hospitais que tratam pacientes de alto risco n&#227;o pare&#231;am ter piores resultados do que outros.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> Para que a mortalidade operat&#243;ria permane&#231;a uma medida v&#225;lida da qualidade da assist&#234;ncia, ela deve estar relacionada ao perfil de risco dos pacientes submetidos &#224; cirurgia.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
    <p>O Euroscore I, publicado em 1999, avaliou 19.030 pacientes submetidos &#224; cirurgia card&#237;aca em 8 pa&#237;ses da Europa, estudando 97 fatores de risco para &#243;bito, dentre os quais foram selecionados aqueles que significativamente afetaram o progn&#243;stico cir&#250;rgico.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> Essas vari&#225;veis s&#227;o apresentadas na <xref ref-type="table" rid="t1">Tabela 1</xref> . Neste estudo, apenas 30% foram submetidos &#224; cirurgia valvar e o n&#250;mero de indiv&#237;duos que apresentou endocardite n&#227;o &#233; mencionado.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
    <p>
      <table-wrap id="t1">
        <label>Tabela 1</label>
        <caption>
          <title>&#8211; Vari&#225;veis inclu&#237;das em escores progn&#243;sticos de cirurgia card&#237;aca (Euroscore I e II e STS-IE)</title>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup width="25%">
            <col/>
            <col/>
            <col/>
            <col/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" style="font-weight:normal">Vari&#225;veis</th>
              <th>EuroScore I</th>
              <th style="font-weight:normal">EuroScore II</th>
              <th style="font-weight:normal">STS-IE Score</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Idade</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>G&#234;nero</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Peso</td>
              <td>
							</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Altura</td>
              <td>
							</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>&#205;ndice de Massa Corp&#243;rea</td>
              <td>
							</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Diabetes Mellitus</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Doen&#231;a Pulmonar Cr&#244;nica</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Arteriopatia Extracard&#237;aca</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Doen&#231;a Arterial Perif&#233;rica</td>
              <td>
							</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Disfun&#231;&#227;o Neurol&#243;gica</td>
              <td style="color:#66fd00">
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Baixa Mobilidade</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Cirurgia card&#237;aca pr&#233;via</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>N&#250;mero de cirurgias pr&#233;vias</td>
              <td>
							</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Cirurgia valvar pr&#233;via</td>
              <td>
							</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Insufici&#234;ncia renal em tratamento conservador</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Insufici&#234;ncia Renal em Hemodi&#225;lise</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Creatinina S&#233;rica/ Clearance de Creatinina</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Arritmia</td>
              <td>
							</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Hipertens&#227;o Arterial Sist&#234;mica</td>
              <td>
							</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>
                <italic>
                  <bold>Endocardite infecciosa em atividade</bold>
                </italic>
              </td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Terapia imunossupressora</td>
              <td>
							</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Infarto do mioc&#225;rdio recente</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Choque cardiog&#234;nico</td>
              <td>
							</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Uso de inotr&#243;picos</td>
              <td>
							</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Bal&#227;o intraa&#243;rtico</td>
              <td>
							</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Classifica&#231;&#227;o NYHA (New York Heart Association)</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Cirurgia n&#227;o coronariana</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Angina Inst&#225;vel (CCS IV)</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Estado Cr&#237;tico Pr&#233;-operat&#243;rio</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Fra&#231;&#227;o de Eje&#231;&#227;o do Ventr&#237;culo Esquerdo</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Hipertens&#227;o Arterial Pulmonar</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Ressuscita&#231;&#227;o</td>
              <td>
							</td>
              <td>
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Procedimento de urg&#234;ncia</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Peso da Interven&#231;&#227;o:</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
            </tr>
            <tr>
              <td>Procedimento &#250;nico n&#227;o coronariano</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>2 Procedimentos</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>3 Procedimentos</td>
              <td style="color:#66fd00">
							</td>
              <td style="color:#66fd00">
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Ruptura septal p&#243;s Infarto do mioc&#225;rdio</td>
              <td style="color:#66fd00">
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </p>
    <p>O Euroscore II, publicado em 2012,<sup><xref ref-type="bibr" rid="B3">3</xref></sup> teve como objetivo atualizar o primeiro modelo, avaliando 22.381 pacientes de 43 pa&#237;ses do mundo, incluindo locais fora da Europa, para criar um escore mais confi&#225;vel, incorporando novas vari&#225;veis e ajustando outras ( <xref ref-type="table" rid="t1">Tabela 1</xref> ). Nesta &#233;poca, j&#225; se sabia que o Euroscore2 superestimava o risco cir&#250;rgico, pois progresso t&#233;cnico em cirurgia card&#237;aca havia sido alcan&#231;ado ao longo da d&#233;cada anterior, com uma diminui&#231;&#227;o da mortalidade ajustada pelo risco. As melhorias no Euroscore foram: clearance de creatinina como uma medida melhor da fun&#231;&#227;o renal do que os valores s&#233;ricos de creatinina; a angina inst&#225;vel definida pelo uso de nitratos intravenosos estava desatualizada; o peso da interven&#231;&#227;o n&#227;o foi avaliado adequadamente no modelo anterior (por exemplo, a troca valvar a&#243;rtica com ou sem cirurgia de revasculariza&#231;&#227;o do mioc&#225;rdio concomitante tinha o mesmo peso) e algumas vari&#225;veis cont&#237;nuas, como n&#250;mero de cirurgias card&#237;acas anteriores e press&#245;es sist&#243;licas da art&#233;ria pulmonar, foram tratadas como dicot&#244;micas.<sup><xref ref-type="bibr" rid="B3">3</xref></sup></p>
    <p>A curva ROC ( <italic>Receiver Operating Characteristic</italic> ) dos escores mostrou uma &#225;rea abaixo da curva (AUC, <italic>area under the curve</italic> ) de 0,78 para o Euroscore log&#237;stico e aditivo e de 0,80 para o Euroscore II. Uma cr&#237;tica ao modelo &#233; que, embora pa&#237;ses n&#227;o europeus tenham sido inclu&#237;dos, a grande maioria dos pacientes era da Espanha, Fran&#231;a, It&#225;lia e Reino Unido, que contribu&#237;ram com 19, 16, 15 e 12 centros, respectivamente.<sup><xref ref-type="bibr" rid="B3">3</xref></sup> Quanto &#224; Am&#233;rica Latina, o Brasil contribuiu com dados de 4 centros, Argentina 1 e Uruguai 1. Al&#233;m disso, o modelo n&#227;o analisou separadamente a cirurgia valvar. De fato, apenas 2,2% dos pacientes (497 em n&#250;meros absolutos) com EI ativa foram inclu&#237;dos.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> Uma limita&#231;&#227;o descrita no estudo foi que todos os centros participaram voluntariamente, o que introduz um vi&#233;s de sele&#231;&#227;o para os dados.<sup><xref ref-type="bibr" rid="B3">3</xref></sup></p>
    <p>Pacientes com EI precisam ser avaliados minuciosamente. Se tomarmos o perfil habitual de um paciente com EI operado no Instituto Nacional de Cardiologia, por exemplo, ele ter&#225; uma creatinina s&#233;rica acima do normal, com escore de 2 pontos; doen&#231;a ativa (em tratamento com antibi&#243;tico para EI no momento da cirurgia), com escore de 3 pontos e disfun&#231;&#227;o ventricular esquerda pelo menos moderada, com escore de 1 ponto, ou seja, o Euroscore dele seria de 6 pontos e a mortalidade prevista seria superior a 11%. N&#227;o raramente, esse paciente foi submetido a cirurgia card&#237;aca anterior (j&#225; que mais de um ter&#231;o tem valvopatia reum&#225;tica e cerca de 10% tiveram EI anterior), o que acrescenta 3 pontos ao escore.<sup><xref ref-type="bibr" rid="B4">4</xref> - <xref ref-type="bibr" rid="B6">6</xref></sup> Portanto, o Euroscore I n&#227;o discrimina bem esse subgrupo de pacientes, pois a maioria provavelmente ir&#225; apresentar um escore de 6 ou mais. Patrat-Delon et al.,<sup><xref ref-type="bibr" rid="B7">7</xref></sup> estudando 149 pacientes operados devido a EI na Fran&#231;a, entre 2002 e 2013, cuja mortalidade hospitalar foi de 21%, chegaram a uma conclus&#227;o semelhante em rela&#231;&#227;o ao EuroSCORE II: subestimou a mortalidade em pacientes com mortalidade prevista acima de 10%.<sup><xref ref-type="bibr" rid="B7">7</xref></sup></p>
    <p>O escore da <italic>Society of Thoracic Surgeons&#8211;Infective Endocarditis</italic> (STS-IE), publicado em 2011,<sup><xref ref-type="bibr" rid="B8">8</xref></sup> tem suas vari&#225;veis mostradas esquematicamente na <xref ref-type="table" rid="t1">Tabela 1</xref> . No subgrupo de pacientes norte-americanos com EI estudados, dos 13.617 pacientes, apenas pouco mais da metade apresentava endocardite ativa no momento da cirurgia.<sup><xref ref-type="bibr" rid="B8">8</xref></sup> A mortalidade geral foi de 8,2%, embora a cirurgia valvar m&#250;ltipla tivesse uma mortalidade operat&#243;ria de 13%. As complica&#231;&#245;es p&#243;s-operat&#243;rias estavam presentes em mais da metade dos pacientes, sendo as mais comuns a ventila&#231;&#227;o prolongada em mais de um quarto.</p>
    <p>No escore STS-IE, os n&#250;meros variam de 0 a 110 pontos e, de acordo com esse modelo, um paciente com 35 pontos teria um risco operat&#243;rio de pelo menos 10% de mortalidade.<sup><xref ref-type="bibr" rid="B8">8</xref></sup> Embora apenas pacientes com EI tenham sido estudados, esse foi um registro volunt&#225;rio exclusivamente de hospitais americanos. Caracter&#237;sticas importantes da EI, como microbiologia, discrimina&#231;&#227;o entre v&#225;lvulas nativas e pr&#243;teses e presen&#231;a de complica&#231;&#245;es intracard&#237;acas (abscesso, f&#237;stula) n&#227;o foram analisadas. Surpreendentemente, 43% dos pacientes foram operados de maneira &#8220;eletiva&#8221;, o que &#233; um cen&#225;rio diferente das outras s&#233;ries.</p>
    <p>Embora n&#227;o sejam espec&#237;ficos para endocardite, o Euroscore e o Euroscore II levam em considera&#231;&#227;o a endocardite ativa como uma vari&#225;vel importante associada &#224; mortalidade operat&#243;ria (ver <xref ref-type="table" rid="t1">Tabela 1</xref> ). &#201; importante ressaltar que foram criados v&#225;rios escores mais espec&#237;ficos para a endocardite, incluindo vari&#225;veis com peso significativo em rela&#231;&#227;o &#224; gravidade dessa condi&#231;&#227;o,<sup><xref ref-type="bibr" rid="B8">8</xref> - <xref ref-type="bibr" rid="B13">13</xref></sup> mostradas na <xref ref-type="table" rid="t1">tabela 1</xref> do artigo de Pivatto Jr F et al.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> As caracter&#237;sticas espec&#237;ficas da EI s&#227;o: EI de v&#225;lvula prot&#233;tica, grande destrui&#231;&#227;o intracard&#237;aca, <italic>Staphylococcus spp.</italic> , pat&#243;geno isolado na cultura de amostras de sangue (ou seja, hemoculturas positivas), presen&#231;a de abscesso, complica&#231;&#245;es perivalvares, microrganismo virulento; al&#233;m destes, h&#225; bloqueio atrioventricular e microrganismos Gram-negativos n&#227;o-HACEK (os &#250;ltimos 2 para o modelo INC-Rio<sup><xref ref-type="bibr" rid="B4">4</xref></sup> ) e envolvimento perivalvar (por exemplo, abscesso anular ou f&#237;stula aortocavit&#225;ria).<sup><xref ref-type="bibr" rid="B13">13</xref></sup> Quando agrupados, al&#233;m do envolvimento da pr&#243;tese, essencialmente o tipo de microrganismo e a destrui&#231;&#227;o da v&#225;lvula (bloqueio AV sinalizando abscesso perivalvar) s&#227;o as caracter&#237;sticas distintivas desses &#8220;escores de EI&#8221; (ver <xref ref-type="table" rid="t2">Tabela 2</xref> ). Mostramos mais dados sobre os escores estudados por Pivatto Jr F et al.,<sup><xref ref-type="bibr" rid="B1">1</xref></sup> na <xref ref-type="table" rid="t3">Tabela 3</xref> e adicionamos a isso os escores INC-Rio<sup><xref ref-type="bibr" rid="B4">4</xref></sup> e DeFeo et al. <sup><xref ref-type="bibr" rid="B13">13</xref></sup> A mortalidade e a AUC dos escores, em rela&#231;&#227;o &#224; popula&#231;&#227;o estudada, s&#227;o mostradas ( <xref ref-type="table" rid="t3">Tabela 3</xref> ). Vale ressaltar que a mortalidade foi vari&#225;vel nas diferentes s&#233;ries e a mortalidade em pacientes operados com EI &#233; pelo menos o dobro da observada em outras cirurgias card&#237;acas (observe as menores taxas de mortalidade para as popula&#231;&#245;es estudadas no Euroscore I e II). O presente estudo n&#227;o prop&#245;e um escore, e foi adicionado &#224; tabela para mostrar a mortalidade em sua s&#233;rie. Neste estudo<sup><xref ref-type="bibr" rid="B1">1</xref></sup> , a melhor taxa de mortalidade O/E foi alcan&#231;ada pelo escore PALSUSE, seguido pelo EuroSCORE log&#237;stico, que demonstrou o maior poder discriminat&#243;rio e foi significativamente superior ao EuroSCORE II, STS-IE, PALSUSE, AEPEI, e RISK-E.</p>
    <p>
      <table-wrap id="t2">
        <label>Tabela 2</label>
        <caption>
          <title>&#8211; Vari&#225;veis inclu&#237;das em escores progn&#243;sticos para mortalidade em cirurgia card&#237;aca em pacientes com endocardite infecciosa submetidos a troca valvar</title>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup width="17%">
            <col/>
            <col/>
            <col/>
            <col/>
            <col/>
            <col/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" style="font-weight:normal">Vari&#225;veis</th>
              <th>PALSUSE2014</th>
              <th style="font-weight:normal">AEPEI 2017</th>
              <th style="font-weight:normal">INC-Rio 2016</th>
              <th style="font-weight:normal">EndoSCORE 2017</th>
              <th style="font-weight:normal">RISK-E 2017</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Endocardite de valva prot&#233;tica</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Idade</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Grande destrui&#231;&#227;o intracard&#237;aca*</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td><italic>Staphylococcus</italic> spp.</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Cirurgia urgente</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Sexo (feminino)</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>EuroScore &#8805;10</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>IMC &gt; 27Kg/m<sup>2</sup></td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Estado pr&#233;-operat&#243;rio cr&#237;tico</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>ClearCreat &lt; 50mL/min</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Classe IV NYHA</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>PSAP &gt; 55mmHg</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>DPOC</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Cr &#8805; 2mg/dL</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>FEVE</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>N&#250;mero de v&#225;lvulas/pr&#243;teses tratadas</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Microrganismo patog&#234;nico isolado em hemoculturas</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Presen&#231;a de abscesso</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Insufici&#234;ncia renal aguda</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>
                <italic>
                  <bold>Choque cardiog&#234;nico</bold>
                </italic>
              </td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Complica&#231;&#245;es perivalvares<sup>&#8225;</sup></td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Choque s&#233;ptico</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Trombocitopenia<sup>&#167;</sup></td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Microrganismo virulento<sup>//</sup></td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>BAV</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>DMID</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>GN n&#227;o-HACEK</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
            <tr>
              <td>Uso de Inotr&#243;picos</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
              <td>
							</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN1">
            <p>
              <italic>*Abscessos ou outros achados de ecocardiografia sugeriram que a infec&#231;&#227;o foi invasiva (comunica&#231;&#227;o entre c&#226;maras, dissec&#231;&#227;o de parede ou grande deisc&#234;ncia valvular). &#8225; Abscesso, pseudoaneurisma, fistula ou deisc&#234;ncia prot&#233;tica; <sup>&#167;</sup> &lt; 150.000 plaquetas/mm<sup>3</sup>. <sup>//</sup>Staphylococcus aureus ou fungos.</italic>
            </p>
          </fn>
          <fn id="TFN2">
            <p>
              <italic>IMC: &#237;ndice de massa corporal; ClearCreat: clearance de creatinina (taxa de filtra&#231;&#227;o glomerular estimada); NYHA: New York Heart Association; PSAP: press&#227;o sist&#243;lica de art&#233;ria pulmonar; DPOC: doen&#231;a pulmonar obstrutiva cr&#244;nica; Cr: creatinina s&#233;rica; FEVE: fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo; BAV: bloqueio atrioventricular; DMID: diabetes mellitus insulinodependente; GN: Gram Negativo; HACEK: Haemophilus spp, Aggregatibacter spp (anteriormente Actinobacillus), Cardiobacterium hominis, Eikenella corrodens, Kingella kingae.</italic>
            </p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </p>
    <p>
      <table-wrap id="t3">
        <label>Tabela 3</label>
        <caption>
          <title>&#8211; &#193;reas sob a curva (AUC) dos escores de risco propostos para avalia&#231;&#227;o de mortalidade em cirurgia card&#237;aca para endocardite infecciosa</title>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup width="14%">
            <col/>
            <col/>
            <col/>
            <col/>
            <col/>
            <col/>
            <col/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" style="font-weight:normal">ESCORE</th>
              <th>AUC</th>
              <th style="font-weight:normal">Mortalidade p&#243;s- operat&#243;ria intra-hospitalar</th>
              <th style="font-weight:normal">Avaliou EI separadamente?</th>
              <th style="font-weight:normal">N estudado</th>
              <th style="font-weight:normal">Pa&#237;s</th>
              <th style="font-weight:normal">Autor, ano</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Logistic EuroSCORE</td>
              <td align="center">0,79</td>
              <td align="center">4,7%</td>
              <td align="center">n&#227;o</td>
              <td align="center">14.799</td>
              <td align="center">Pa&#237;ses europeus*</td>
              <td align="center">Nashef 1999</td>
            </tr>
            <tr>
              <td>EuroSCORE II</td>
              <td align="center">0,81</td>
              <td align="center">3,9%</td>
              <td align="center">n&#227;o</td>
              <td align="center">22.381</td>
              <td align="center">Pa&#237;ses europeus**</td>
              <td align="center">Nashef 2012</td>
            </tr>
            <tr>
              <td>STS-IE</td>
              <td align="center">0,76</td>
              <td align="center">8,2%</td>
              <td align="center">sim</td>
              <td align="center">13.617</td>
              <td align="center">EUA</td>
              <td align="center">Gaca 2011</td>
            </tr>
            <tr>
              <td>&#8220;De Feo&#8221;***</td>
              <td align="center">0,88</td>
              <td align="center">9,1%</td>
              <td align="center">sim</td>
              <td align="center">440</td>
              <td align="center">It&#225;lia</td>
              <td align="center">De Feo 2012</td>
            </tr>
            <tr>
              <td>PALSUSE</td>
              <td align="center">0,68</td>
              <td align="center">24,3%</td>
              <td align="center">sim</td>
              <td align="center">437</td>
              <td align="center">Espanha</td>
              <td align="center">Mart&#237;nez-Sell&#233;s 2014</td>
            </tr>
            <tr>
              <td>INC-Rio</td>
              <td align="center">0,97</td>
              <td align="center">17,5%</td>
              <td align="center">sim</td>
              <td align="center">154</td>
              <td align="center">Brasil</td>
              <td align="center">Martins 2016</td>
            </tr>
            <tr>
              <td>RISK-E</td>
              <td align="center">0,82</td>
              <td align="center">28,6%</td>
              <td align="center">sim</td>
              <td align="center">671</td>
              <td align="center">Fran&#231;a e Espanha</td>
              <td align="center">Olmos 2017</td>
            </tr>
            <tr>
              <td>AEPEI</td>
              <td align="center">0,78</td>
              <td align="center">15,5%</td>
              <td align="center">sim</td>
              <td align="center">361</td>
              <td align="center">Fran&#231;a e It&#225;lia</td>
              <td align="center">Gatti 2017</td>
            </tr>
            <tr>
              <td>EndoSCORE</td>
              <td align="center">0,85</td>
              <td align="center">11%</td>
              <td align="center">sim</td>
              <td align="center">2.715</td>
              <td align="center">It&#225;lia</td>
              <td align="center">Di Mauro 2017</td>
            </tr>
            <tr>
              <td>N&#227;o foi criado</td>
              <td align="center">N&#227;o avaliada</td>
              <td align="center">29%</td>
              <td align="center">sim</td>
              <td align="center">107</td>
              <td align="center">Brasil</td>
              <td align="center">Pivatto Jr F, 2020</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN3">
            <p>
              <italic>AUC: &#225;rea sob a curva (area under the curve); EI: endocardite infecciosa. *N&#227;o est&#225; discriminado que pa&#237;ses participaram. **A maior parte dos centros de investiga&#231;&#227;o eram da Fran&#231;a, It&#225;lia e Espanha; pa&#237;ses da Am&#233;rica do Sul e do Norte, &#193;sia e &#193;frica tiveram participa&#231;&#227;o pequena. EUA: Estados Unidos da Am&#233;rica. *** Somente pacientes com EI de v&#225;lvula nativa foram estudados; nenhum nome foi dado ao escore.</italic>
            </p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </p>
    <p>Em conclus&#227;o, v&#225;rios grupos est&#227;o em busca de um escore adequado para prever a mortalidade em pacientes operados por EI. O Euroscore I e II, amplamente utilizados, e o STS-IE, foram estudados comparativamente aos novos escores propostos, alguns dos quais (por exemplo, PALSUSE) inclu&#237;ram partes do Euroscore. No Brasil, apenas 2 estudos (o presente, com 107 pacientes, e o de Martins et al.,<sup><xref ref-type="bibr" rid="B4">4</xref></sup> com 154) abordaram o desempenho dos escores na EI, ambos com pequeno n&#250;mero. No primeiro, os autores conclu&#237;ram que, apesar da disponibilidade de escores espec&#237;ficos, o EuroSCORE log&#237;stico era o melhor para prever a mortalidade em sua coorte e nenhum escore foi proposto; no segundo, os escores de EI mencionados n&#227;o foram avaliados (a maioria deles publicada ap&#243;s 2016), mas a sensibilidade e especificidade do Euroscore I foram de 81,5% e 63%; para Euroscore II, 29,6% e 97,6%, e para o STS-IE 7,4% e 98,4%, respectivamente. Os valores da AUC foram de 0,86 (Euroscore I), 0,90 (Euroscore II) e 0,85 (STS-IE). Na an&#225;lise multivariada, as vari&#225;veis consideradas estatisticamente significantes para &#243;bito foram bloqueio AV, choque cardiog&#234;nico, diabetes mellitus insulinodependente, microrganismos Gram-negativos n&#227;o-HACEK e uso de inotr&#243;picos. Estes foram inclu&#237;dos em um modelo, o INC-Rio,<sup><xref ref-type="bibr" rid="B4">4</xref></sup> com sensibilidade calculada de 88,9% e especificidade de 91,8%; a AUC foi de 0,97. Casalino et al.<sup><xref ref-type="bibr" rid="B14">14</xref></sup> estudaram todos os tipos de cirurgia valvar em 440 pacientes, nos quais a taxa de mortalidade foi de 16,0% (6,0% em cirurgia eletiva e 34,0% em cirurgia de emerg&#234;ncia / urg&#234;ncia) e constataram que a AUC foi de 0,76 para o EuroSCORE aditivo e log&#237;stico e 0,81 para o EuroSCORE II. Eles conclu&#237;ram que os modelos de EuroSCORE tinham boa capacidade discriminat&#243;ria, embora a calibra&#231;&#227;o estivesse comprometida devido &#224; subestima&#231;&#227;o da mortalidade.</p>
    <p>Acreditamos que um estudo multinacional no Brasil seria de suma import&#226;ncia, com maior n&#250;mero de pacientes, para propor e validar um escore, uma vez que os pacientes com EI em nosso pa&#237;s diferem drasticamente daqueles dos pa&#237;ses da Am&#233;rica do Norte ou da Europa, principalmente devido &#224; alta propor&#231;&#227;o de valvopatia reum&#225;tica, EI causada por estreptococos do grupo <italic>viridans</italic> , maior demora no diagn&#243;stico e idade mais jovem.</p>
  </body>
  <back>
    <ack>
      <title>Agradecimentos</title>
      <p>Agradecemos ao Dr. Carlos Rochitte, editor-chefe dos Arquivos Brasileiros de Cardiologia, pela oportunidade de debater endocardite infecciosa nesta conceituada revista, e a nossos colegas do Instituto Nacional de Cardiologia pela parceria na &#8220;Equipe de Endocardite&#8221; e no Mestrado Profissional em Ci&#234;ncias Cardiovasculares.</p>
    </ack>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. Pivatto Jr F, Bellagamba CCA, Pianca EG, Fernandes FS, Butzke M, Busato SB et al. Analysis of Risk Scores to Predict Mortality in Patients Undergoing Cardiac Surgery for Endocarditis. Arq Bras Cardiol. 2020; 114(3):518-524</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pivatto</surname>
              <given-names>F</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Bellagamba</surname>
              <given-names>CCA</given-names>
            </name>
            <name>
              <surname>Pianca</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Fernandes</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Butzke</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Busato</surname>
              <given-names>SB</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Analysis of Risk Scores to Predict Mortality in Patients Undergoing Cardiac Surgery for Endocarditis</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2020</year>
          <volume>114</volume>
          <issue>3</issue>
          <fpage>518</fpage>
          <lpage>524</lpage>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg. 1999;15(6):816-22.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roques</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Nashef</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Michel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gauducheau</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>de Vincentiis</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Baudet</surname>
              <given-names>E</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients</article-title>
          <source>Eur J Cardiothorac Surg</source>
          <year>1999</year>
          <volume>15</volume>
          <issue>6</issue>
          <fpage>816</fpage>
          <lpage>822</lpage>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. Eur J Cardiothorac Surg. 2012;41(4):734-44.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nashef</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Roques</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sharples</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Nilsson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Goldstone</surname>
              <given-names>AR</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>EuroSCORE II</article-title>
          <source>Eur J Cardiothorac Surg</source>
          <year>2012</year>
          <volume>41</volume>
          <issue>4</issue>
          <fpage>734</fpage>
          <lpage>744</lpage>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. Martins ABB. Avalia&#231;&#227;o do desempenho de escores de progn&#243;stico de cirurgia card&#237;aca em pacientes submetidos &#224; troca valvar por endocardite infecciosa no Instituto Nacional de Cardiologia, anos de 2006 a 2016. [disserta&#231;&#227;o]. Rio de Janeiro: Instituto Nacional de Cardiologia; 2016.</mixed-citation>
        <element-citation publication-type="thesis">
          <person-group person-group-type="author">
            <name>
              <surname>Martins</surname>
              <given-names>ABB</given-names>
            </name>
          </person-group>
          <source>Avalia&#231;&#227;o do desempenho de escores de progn&#243;stico de cirurgia card&#237;aca em pacientes submetidos &#224; troca valvar por endocardite infecciosa no Instituto Nacional de Cardiologia, anos de 2006 a 2016</source>
          <comment>disserta&#231;&#227;o</comment>
          <publisher-loc>Rio de Janeiro</publisher-loc>
          <publisher-name>Instituto Nacional de Cardiologia</publisher-name>
          <year>2016</year>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5. Brand&#227;o TJ, Januario-da-Silva CA, Correia MG, Zappa M, Abrantes JA, Dantas AM, et al. Histopathology of valves in infective endocarditis, diagnostic criteria and treatment considerations. Infection. 2017;45(2):199-207.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brand&#227;o</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Januario-da-Silva</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Correia</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Zappa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abrantes</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Dantas</surname>
              <given-names>AM</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Histopathology of valves in infective endocarditis, diagnostic criteria and treatment considerations</article-title>
          <source>Infection</source>
          <year>2017</year>
          <volume>45</volume>
          <issue>2</issue>
          <fpage>199</fpage>
          <lpage>207</lpage>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6. Monteiro TS, Correia MG, Golebiovski WF, Barbosa GIF, Weksler C, Lamas CC. Asymptomatic and symptomatic embolic events in infective endocarditis: associated factors and clinical impact. Braz J Infect Dis. 2017;21(3):240-7.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Monteiro</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Correia</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Golebiovski</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Barbosa</surname>
              <given-names>GIF</given-names>
            </name>
            <name>
              <surname>Weksler</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lamas</surname>
              <given-names>CC</given-names>
            </name>
          </person-group>
          <article-title>Asymptomatic and symptomatic embolic events in infective endocarditis: associated factors and clinical impact</article-title>
          <source>Braz J Infect Dis</source>
          <year>2017</year>
          <volume>21</volume>
          <issue>3</issue>
          <fpage>240</fpage>
          <lpage>247</lpage>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7. Patrat-Delon S, Rouxel A, Gacouin A, Revest M, Fl&#233;cher E, Fouquet O, et al. EuroSCORE II underestimates mortality after cardiac surgery for infective endocarditis. Eur J Cardiothorac Surg 2016;49(3):944-51.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patrat-Delon</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rouxel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gacouin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Revest</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fl&#233;cher</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Fouquet</surname>
              <given-names>O</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>EuroSCORE II underestimates mortality after cardiac surgery for infective endocarditis</article-title>
          <source>Eur J Cardiothorac Surg</source>
          <year>2016</year>
          <volume>49</volume>
          <issue>3</issue>
          <fpage>944</fpage>
          <lpage>951</lpage>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation>8. Gaca JG, Sheng S, Daneshmand MA, O&#8217;Brien S, Rankin JS, Brennan JM, et al. Outcomes for endocarditis surgery in North America: a simplified risk scoring system. J Thorac Cardiovasc Surg 2011;141(1):98-106.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gaca</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Sheng</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Daneshmand</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>O&#8217;Brien</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rankin</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Brennan</surname>
              <given-names>JM</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Outcomes for endocarditis surgery in North America: a simplified risk scoring system</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <year>2011</year>
          <volume>141</volume>
          <issue>1</issue>
          <fpage>98</fpage>
          <lpage>106</lpage>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>9. Mart&#237;nez-Sell&#233;s M, Mu&#241;oz P, Arn&#225;iz A, Moreno M, G&#225;lvez J, Rodr&#237;guez-Roda J, et al. Valve surgery in active infective endocarditis: a simple score to predict in-hospital prognosis. Int J Cardiol. 2014;175(1):133-7.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mart&#237;nez-Sell&#233;s</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mu&#241;oz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Arn&#225;iz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Moreno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>G&#225;lvez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rodr&#237;guez-Roda</surname>
              <given-names>J</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Valve surgery in active infective endocarditis: a simple score to predict in-hospital prognosis</article-title>
          <source>Int J Cardiol</source>
          <year>2014</year>
          <volume>175</volume>
          <issue>1</issue>
          <fpage>133</fpage>
          <lpage>137</lpage>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation>10. Gatti G, Perrotti A, Obadia J, Duval X, Iung B, Alla F, et al. Simple scoring system to predict in hospital mortality after surgery for infective endocarditis. J Am Heart Assoc. 2017;6(7):pii:e004806.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gatti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Perrotti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Obadia</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Duval</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Iung</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Alla</surname>
              <given-names>F</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Simple scoring system to predict in hospital mortality after surgery for infective endocarditis</article-title>
          <source>J Am Heart Assoc</source>
          <year>2017</year>
          <volume>6</volume>
          <issue>7</issue>
          <elocation-id>e004806</elocation-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation>11. Di Mauro M, Dato GMA, Barili F, Gelsomino S, Sant&#232; P, Corte AD, et al. Corrigendum to &#8220;A predictive model for early mortality after surgical treatment of heart valve or prosthesis infective endocarditis. The EndoSCORE&#8221;. Int J Cardiol. 2018 May 1;258:337.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Di Mauro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dato</surname>
              <given-names>GMA</given-names>
            </name>
            <name>
              <surname>Barili</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gelsomino</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sant&#232;</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Corte</surname>
              <given-names>AD</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Corrigendum to &#8220;A predictive model for early mortality after surgical treatment of heart valve or prosthesis infective endocarditis. The EndoSCORE&#8221;</article-title>
          <source>Int J Cardiol</source>
          <year>2018</year>
          <month>05</month>
          <day>1</day>
          <volume>258</volume>
          <size units="pages">337</size>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation>12. Olmos C, Vilacosta I, Habib G, Maroto L, Fern&#225;ndez C, L&#243;pez J, et al. Risk score for cardiac surgery in active left-sided infective endocarditis. Heart. 2017;103(18):1435-42.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olmos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vilacosta</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Habib</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Maroto</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fern&#225;ndez</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>L&#243;pez</surname>
              <given-names>J</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Risk score for cardiac surgery in active left-sided infective endocarditis</article-title>
          <source>Heart</source>
          <year>2017</year>
          <volume>103</volume>
          <issue>18</issue>
          <fpage>1435</fpage>
          <lpage>1442</lpage>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation>13. De Feo M, Cotrufo M, Carozza A, De Santo LS, Amendolara F, Giordano S, et al. The need for a specific risk prediction system in native valve infective endocarditis surgery. ScientificWorldJournal. 2012;2012:307571.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Feo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cotrufo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carozza</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>De Santo</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Amendolara</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Giordano</surname>
              <given-names>S</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>The need for a specific risk prediction system in native valve infective endocarditis surgery</article-title>
          <source>ScientificWorldJournal</source>
          <year>2012</year>
          <volume>2012</volume>
          <elocation-id>307571</elocation-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation>14. Casalino R, Tarasoutchi F, Spina G, Katz M, Bacelar A, Sampaio R, et al. EuroSCORE models in a cohort of patients with valvular heart disease and a high prevalence of rheumatic fever submitted to surgical procedures. PLoS One. 2015;10(2):e0118357.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Casalino</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tarasoutchi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Spina</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Katz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bacelar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sampaio</surname>
              <given-names>R</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>EuroSCORE models in a cohort of patients with valvular heart disease and a high prevalence of rheumatic fever submitted to surgical procedures</article-title>
          <source>PLoS One</source>
          <year>2015</year>
          <volume>10</volume>
          <issue>2</issue>
          <elocation-id>e0118357</elocation-id>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="other" id="fn1">
        <p>
          <italic>Minieditorial referente ao artigo: An&#225;lise de Escores de Risco para Predi&#231;&#227;o de Mortalidade em Pacientes Submetidos &#224; Cirurgia Card&#237;aca por Endocardite</italic>
        </p>
      </fn>
    </fn-group>
    <fn-group>
      <fn fn-type="financial-disclosure" id="fn2">
        <p>Fontes de Financiamento. Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado do Rio de Janeiro (FAPERJ; bolsa Jovem Cientista do Nosso Estado, # E26/202.782/2015).</p>
      </fn>
    </fn-group>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Editorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Prognostic Scores for Mortality in Cardiac Surgery for Infective Endocarditis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Martins</surname>
            <given-names>Alexandre Bahia Barreiras</given-names>
          </name>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-5561-999X</contrib-id>
          <name>
            <surname>Lamas</surname>
            <given-names>Cristiane da Cruz</given-names>
          </name>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3001">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4001">
            <sup>4</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1001">
        <label>1</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Unidade Cardiointensiva - Cl&#237;nica S&#227;o Vicente da G&#225;vea, Rio de Janeiro, RJ - Brazil</institution>
      </aff>
      <aff id="aff2001">
        <label>2</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Coordena&#231;&#227;o de Ensino e Pesquisa - Instituto Nacional de Cardiologia, Rio de Janeiro, RJ - Brazil</institution>
      </aff>
      <aff id="aff3001">
        <label>3</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Escola de Ci&#234;ncias da Sa&#250;de - Universidade do Grande Rio (Unigranrio), Rio de Janeiro, RJ - Brazil</institution>
      </aff>
      <aff id="aff4001">
        <label>4</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Centro Hospitalar - Instituto Nacional de Infectologia Evandro Chagas - Fiocruz, Rio de Janeiro, RJ &#8211; Brazil</institution>
      </aff>
      <author-notes>
        <corresp id="c01001">Mailing Address: Cristiane da Cruz Lamas &#8226; Instituto Nacional de Cardiologia - Coordena&#231;&#227;o de Ensino e Pesquisa - Rua das Laranjeiras, 374 5&#186; andar. Postal Code 22240-006, Rio de Janeiro, RJ &#8211; Brazil Email: cristianelamas@gmail.com</corresp>
      </author-notes>
      <kwd-group xml:lang="en">
        <kwd>Endocarditis/surgery</kwd>
        <kwd>Hospital Mortality</kwd>
        <kwd>Cardiac Surgery/mortalidade</kwd>
        <kwd>Prognosis</kwd>
        <kwd>Scores</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>The article by Pivatto F Jr et al.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> allows us to discuss the important issue of prognostic scores in patients who have cardiac surgery for infective endocarditis (IE).<sup><xref ref-type="bibr" rid="B1">1</xref></sup> The management of left- sided IE often involves surgery during the index admission, and the main challenge is to rapidly and correctly identify patients at high risk and to transfer them to institutions with a surgical team with expertise in endocarditis surgery.</p>
      <p>Prognostic scores are important for several reasons: a reasonable estimate of the risk of death is important in clinical decision-making regarding surgical indication; the estimate is necessary to inform patients and their families of the surgical risk; risk stratification permits a fair comparison of cardiac surgery results, so that surgeons and hospitals treating high-risk patients will not appear to have worse results than others.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> For operative mortality to remain a valid measure of quality of care, it must be related to the risk profile of the patients receiving surgery.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
      <p>Euroscore I, published in 1999, evaluated 19,030 patients submitted to cardiac surgery in 8 countries in Europe, studying 97 risk factors for death, and among those, the ones that significantly affected surgical prognosis were selected.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> These variables are presented in <xref ref-type="table" rid="t1001">Table 1</xref> . In this study, only 30% were submitted to valve surgery, and the number of individuals who had endocarditis is not mentioned.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
      <p>
        <table-wrap id="t1001">
          <label>Table 1</label>
          <caption>
            <title>&#8211; Variables included in prognostic scores for cardiac surgery (Euroscore I and II and STS-IE)</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="25%">
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" style="font-weight:normal">Variables</th>
                <th>EuroScore I</th>
                <th style="font-weight:normal">EuroScore II</th>
                <th style="font-weight:normal">STS-IE Score</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Age</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Gender</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Weight</td>
                <td>
								</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Height</td>
                <td>
								</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Body Mass Index</td>
                <td>
								</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Diabetes Mellitus</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Chronic Pulmonary Disease</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Extracardiac arteriopathy</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Peripheral Arterial Disease</td>
                <td>
								</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Neurological Dysfunction</td>
                <td style="color:#66fd00">
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Low Mobility</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Previous cardiac surgery</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Number of previous surgeries</td>
                <td>
								</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Previous valvar surgery</td>
                <td>
								</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Renal failure under conservative treatment</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Renal Failure under Hemodialysis</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Serum Creatinine / Creatinine Clearance</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Arrythmia</td>
                <td>
								</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Systemic Arterial Hypertension</td>
                <td>
								</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>
                  <italic>
                    <bold>Active infective endocarditis</bold>
                  </italic>
                </td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Immunosuppressive therapy</td>
                <td>
								</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Recent myocardial infarction</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Cardiogenic shock</td>
                <td>
								</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Inotropic use</td>
                <td>
								</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Intra-aortic balloon</td>
                <td>
								</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>NYHA (New York Heart Association) Classification</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Non-coronary surgery</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Unstable Angina (CCS IV)</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Preoperative Critical State</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Left Ventricular Ejection Fraction</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Pulmonary Arterial Hypertension</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Resuscitation</td>
                <td>
								</td>
                <td>
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Urgency Procedure</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Intervention weight:</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
              </tr>
              <tr>
                <td>Single non-coronary procedure</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>2 Procedures</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>3 Procedures</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Septal rupture after myocardial infarction</td>
                <td style="color:#66fd00">
								</td>
                <td style="color:#66fd00">
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </p>
      <p>Euroscore II, published in 2012,<sup><xref ref-type="bibr" rid="B3">3</xref></sup> had the goal of updating the first model by evaluating 22,381 patients from 43 countries in the world, including sites outside Europe, so as to create a more reliable score, incorporating new variables and adjusting others ( <xref ref-type="table" rid="t1001">Table 1</xref> ). At this time, it was already known that the Euroscore<sup><xref ref-type="bibr" rid="B2">2</xref></sup> superestimated the surgical risk as technical progress in cardiac surgery along the previous decade had been made, with a mortality decrease adjusted by risk. Improvements to Euroscore were: creatinine clearance as a better measure of renal function than serum creatinine values; unstable angina defined by the use of intravenous nitrates was outdated; weight of intervention was not properly assessed in the previous model (for example, aortic valve replacement with or without concurrent coronary artery bypass grafting had the same weight) and some continuous variables, such as number of previous cardiac surgeries and pulmonary artery systolic pressures were treated as a dichotomic variable.<sup><xref ref-type="bibr" rid="B3">3</xref></sup></p>
      <p>The receiving operator curve (ROC) of the scores showed an area under the curve (AUC) of 0.78 for the logistic and additive Euroscore and of 0.80 for Euroscore II. A criticism to the model is, that although non-European countries were included, the vast majority of patients were from Spain, France, Italy and the United Kingdom, who contributed with 19, 16, 15 and 12 sites respectively.<sup><xref ref-type="bibr" rid="B3">3</xref></sup> As for Latin America, Brazil contributed with data from 4 centers, Argentina 1 and Uruguay 1. Also, the model did not analyze valve surgery separately. In fact, only 2.2% of patients (497 in absolute numbers) with active IE had been included.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> A limitation outlined in the study was that all centers participated voluntarily, what introduces selection bias to the data.<sup><xref ref-type="bibr" rid="B3">3</xref></sup></p>
      <p>Patients with IE must be thoroughly assessed. If we consider the usual profile of a patient with IE who is operated at Instituto Nacional de Cardiologia, for example, he or she will have a serum creatinine above normal, scoring 2 points; active disease (under antibiotic treatment for IE at the time of surgery), scoring 3 points, and at least moderate left ventricular dysfunction, scoring 1, that is, with a total Euroscore of 6 and anticipated mortality of over 11%. Not infrequently, this patient previously had cardiac surgery (as over a third have rheumatic valvopathy and about 10% previously had IE), which adds 3 points to the total score.<sup><xref ref-type="bibr" rid="B4">4</xref> - <xref ref-type="bibr" rid="B6">6</xref></sup> Therefore, Euroscore I does not discriminate well this subset of patients, as most will probably fall into the 6+ score. Patrat-Delon et al.,<sup><xref ref-type="bibr" rid="B7">7</xref></sup> studying 149 patients operated for IE in France, between 2002 and 2013, of which in-hospital mortality was 21%, came to a similar conclusion regarding EuroSCORE II: it underestimated mortality in patients with predicted mortality over 10%.<sup><xref ref-type="bibr" rid="B7">7</xref></sup></p>
      <p>The Society of Thoracic Surgeons&#8211;Infective Endocarditis (STS-IE) score, published in 2011,<sup><xref ref-type="bibr" rid="B8">8</xref></sup> has its variables shown schematically in <xref ref-type="table" rid="t1001">Table 1</xref> . In the subset of North American patients with IE studied in its development, of the 13,617 patients, only over half had active endocarditis at the time of surgery.<sup><xref ref-type="bibr" rid="B8">8</xref></sup> Overall mortality was 8.2%, although multiple valve surgery had an operative mortality of 13%. Postoperative complications were present in more than half the patients, most common of which were prolonged ventilation in over a quarter.</p>
      <p>In the STS-IE score, numbers vary from 0-110 points and, according to this model, a patient with 35 points would have an operative risk of at least 10% mortality.<sup><xref ref-type="bibr" rid="B8">8</xref></sup> Although only patients with IE were studied, this was a voluntary registry of American hospitals only. Important features of IE, such as microbiology, the discrimination between native and prosthetic valves and the presence of intracardiac complications (abscess, fistula) were not analyzed. Surprisingly, 43% of the patients were operated on &#8220;electively&#8221;, which is a different scenario from other series.</p>
      <p>Although not specific for endocarditis, Euroscore and Euroscore II take into account active endocarditis as an important variable associated with operative mortality (see <xref ref-type="table" rid="t1001">Table 1</xref> ). Importantly, several scores have been created, which are more specific to endocarditis, involving variables that carry a significant weight regarding severity of this condition,<sup><xref ref-type="bibr" rid="B8">8</xref> - <xref ref-type="bibr" rid="B13">13</xref></sup> shown in <xref ref-type="table" rid="t1001">table 1</xref> of the article by Pivatto Jr F et al.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Features specific to IE are prosthetic valve IE, large intracardiac destruction, <italic>Staphylococcus</italic> spp., pathogen isolated from a blood specimen culture (i.e., positive blood cultures), presence of abscess, perivalvar complications, virulent microorganism; besides these, there is atrioventricular block and non-HACEK Gram negatives (the last 2 for INC-Rio model<sup><xref ref-type="bibr" rid="B4">4</xref></sup> ) and perivalvular involvement (ex. annular abscess or aortocavitary fistula).<sup><xref ref-type="bibr" rid="B13">13</xref></sup> When grouped, in addition to prosthesis involvement, essentially type of microorganism and valve destruction (AV block signaling perivalvular abscess) are the distinctive features in these &#8220;IE scores&#8221; ( see <xref ref-type="table" rid="t2001">Table 2</xref> ). We have shown more data on the scores studied by Pivatto Jr F et al.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> in <xref ref-type="table" rid="t3001">table 3</xref> , and we have added to this the INC-Rio<sup><xref ref-type="bibr" rid="B4">4</xref></sup> and the DeFeo scores.<sup><xref ref-type="bibr" rid="B13">13</xref></sup> Mortality and AUC of the scores, relative to their studied population, are shown ( <xref ref-type="table" rid="t3001">Table 3</xref> ). It is noteworthy that mortality was variable in the different series, and mortality in patients operated with IE was at least double that seen in other types of cardiac surgery (note the lower mortality rates for the populations studied in Euroscore I and II). The present study does not propose a score, and it was added to the table so as to show mortality in their series. In this study<sup><xref ref-type="bibr" rid="B1">1</xref></sup> , the best O/E mortality ratio was achieved by the PALSUSE score, followed by the logistic EuroSCORE, which had the highest discriminatory power and was significantly superior to EuroSCORE II, STS-IE, PALSUSE, AEPEI and RISK-E.</p>
      <p>
        <table-wrap id="t2001">
          <label>Table 2</label>
          <caption>
            <title>&#8211; Variables included in prognostic scores for cardiac surgery mortality in patients with infective endocarditis undergoing valve replacement</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="17%">
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" style="font-weight:normal">Variables</th>
                <th>PALSUSE2014</th>
                <th style="font-weight:normal">AEPEI 2017</th>
                <th style="font-weight:normal">INC-Rio 2016</th>
                <th style="font-weight:normal">EndoSCORE 2017</th>
                <th style="font-weight:normal">RISK-E 2017</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Prosthetic valve endocarditis</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Age</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Large intracardiac destruction*</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>
                  <italic>Staphylococcus spp.</italic>
                </td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Urgent surgery</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Gender (female)</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>EuroScore &#8805;10</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>BMI &gt; 27Kg/m<sup>2</sup></td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Critical preoperative state</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>ClearCreat &lt; 50mL/min</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Class IV NYHA</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>PASP &gt; 55mmHg</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>COPD</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Cr &#8805; 2mg/dL</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>LVEF</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Number of valves / prostheses treated</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Pathogenic microorganism isolated in blood cultures</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Presence of abscess</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Acute renal failure</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Cardiogenic shock</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Perivalvar complications<sup>&#8225;</sup></td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Septic shock</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Thrombocytopenia<sup>&#167;</sup></td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Virulent microorganism<sup>//</sup></td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Atrioventricular block</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>IDDM</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Non-HACEK Gram negatives</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
              <tr>
                <td>Inotropic use</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
                <td>
								</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN1001">
              <p>
                <italic>*Abscesses or other echocardiographic findings suggested that the infection was invasive (inter-chamber communication, wall dissection or major valve dehiscence).</italic>
              </p>
            </fn>
            <fn id="TFN2001">
              <p>
                <italic><sup>&#8225;</sup>Abscess, pseudoaneurysm, prosthetic fistula or dehiscence;<sup>&#167;</sup>&lt; 150,000 platelets/mm<sup>3</sup>.</italic>
              </p>
            </fn>
            <fn id="TFN3001">
              <p>
                <italic><sup>//</sup>Staphylococcus aureus or fungi.</italic>
              </p>
            </fn>
            <fn id="TFN4001">
              <p>
                <italic>BMI: body mass index; ClearCreat = creatinine clearance (estimated glomerular filtration rate); NYHA: New York Heart Association; PASP = pulmonary artery systolic pressure; COPD = chronic obstructive pulmonary disease; Cr = serum creatinine; LVEF = left ventricular ejection fraction; AVB: atrioventricular block; IDDM = insulin-dependent diabetes mellitus; GN: Gram-Negative; HACEK = Haemophilus spp, Aggregatibacter spp (formerly Actinobacillus), Cardiobacterium hominis, Eikenella corrodens, Kingella kingae.</italic>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>
        <table-wrap id="t3001">
          <label>Table 3</label>
          <caption>
            <title>&#8211; Areas under the curve (AUC) of the proposed risk scores for assessing mortality in cardiac surgery for infective endocarditis</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="14%">
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" style="font-weight:normal">SCORE</th>
                <th>AUC</th>
                <th style="font-weight:normal">Postoperative intrahospital mortality</th>
                <th style="font-weight:normal">Evaluated IE separately?</th>
                <th style="font-weight:normal">N. studied</th>
                <th style="font-weight:normal">Country</th>
                <th style="font-weight:normal">Author, year</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Logistic EuroSCORE</td>
                <td align="center">0.79</td>
                <td align="center">4.7%</td>
                <td align="center">no</td>
                <td align="center">14,799</td>
                <td align="center">European countries*</td>
                <td align="center">Nashef 1999</td>
              </tr>
              <tr>
                <td>EuroSCORE II</td>
                <td align="center">0.81</td>
                <td align="center">3.9%</td>
                <td align="center">no</td>
                <td align="center">22,381</td>
                <td align="center">European countries**</td>
                <td align="center">Nashef 2012</td>
              </tr>
              <tr>
                <td>STS-IE</td>
                <td align="center">0.76</td>
                <td align="center">8.2%</td>
                <td align="center">yes</td>
                <td align="center">13,617</td>
                <td align="center">USA</td>
                <td align="center">Gaca 2011</td>
              </tr>
              <tr>
                <td>&#8220;De Feo&#8221;***</td>
                <td align="center">0.88</td>
                <td align="center">9.1%</td>
                <td align="center">yes</td>
                <td align="center">440</td>
                <td align="center">Italy</td>
                <td align="center">De Feo 2012</td>
              </tr>
              <tr>
                <td>PALSUSE</td>
                <td align="center">0.68</td>
                <td align="center">24.3%</td>
                <td align="center">yes</td>
                <td align="center">437</td>
                <td align="center">Spain</td>
                <td align="center">Mart&#237;nez-Sell&#233;s 2014</td>
              </tr>
              <tr>
                <td>INC-Rio</td>
                <td align="center">0.97</td>
                <td align="center">17.5%</td>
                <td align="center">yes</td>
                <td align="center">154</td>
                <td align="center">Brazil</td>
                <td align="center">Martins 2016</td>
              </tr>
              <tr>
                <td>RISK-E</td>
                <td align="center">0.82</td>
                <td align="center">28.6%</td>
                <td align="center">yes</td>
                <td align="center">671</td>
                <td align="center">France and Spain</td>
                <td align="center">Olmos 2017</td>
              </tr>
              <tr>
                <td>AEPEI</td>
                <td align="center">0.78</td>
                <td align="center">15.5%</td>
                <td align="center">yes</td>
                <td align="center">361</td>
                <td align="center">France and Italy</td>
                <td align="center">Gatti 2017</td>
              </tr>
              <tr>
                <td>EndoSCORE</td>
                <td align="center">0.85</td>
                <td align="center">11%</td>
                <td align="center">yes</td>
                <td align="center">2,715</td>
                <td align="center">Italy</td>
                <td align="center">Di Mauro 2017</td>
              </tr>
              <tr>
                <td>Not created</td>
                <td align="center">Not assessed</td>
                <td align="center">29%</td>
                <td align="center">yes</td>
                <td align="center">107</td>
                <td align="center">Brazil</td>
                <td align="center">Pivatto Jr F, 2020</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN5001">
              <p>
                <italic>AUC: area under the curve; IE: infective endocarditis. *Participating countries were not discriminated. **Most of the research centers were located in France, Italy and Spain; countries in South and North America, Asia and Africa had a small participation. USA: United States of Am&#233;rica. ***Only patients with native valve IE were studied; no name was given to the score.</italic>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>In conclusion, several groups are in search of an adequate score to predict mortality in patients operated for IE. The widely used Euroscore I and II, and the STS-IE have been studied comparatively to the new proposed scores, some of which (for ex., PALSUSE) have included parts of Euroscore to them. In Brazil, only 2 studies (the present one, with 107 patients, and the one by Martins et al.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> with 154) have addressed the performance of scores in IE, both with small numbers. In the first, the authors concluded that, despite the availability of specific scores, the logistic EuroSCORE was the best to predict mortality in their cohort and no score was proposed; in the second, the mentioned IE scores were not evaluated (most of them published after 2016), but the sensitivity and specificity of Euroscore I was 81.5% and 63%; for Euroscore II , 29.6% and 97.6%, and for STS-IE 7.4% and 98.4%, respectively. AUC values were 0.86 (Euroscore I), 0.90 (Euroscore II) and 0.85 (STS-IE). In the multivariate analysis, the variables found to be statistically significant for death were AV block, cardiogenic shock, insulin-dependent diabetes mellitus, non-HACEK Gram negative microorganisms and inotropic use. These were included in a model, INC-Rio<sup><xref ref-type="bibr" rid="B4">4</xref></sup> with a calculated sensitivity of 88.9% and specificity of 91.8%; AUC was 0.97. Casalino et al.<sup><xref ref-type="bibr" rid="B14">14</xref></sup> have studied all-type valvular surgery in 440 patients, in which mortality rate was 16.0% (6.0% in elective surgery and 34.0% in emergency/urgency surgery), and found the AUC was 0.76 for additive and logistic EuroSCORE and 0.81 for EuroSCORE II. They concluded that the EuroSCORE models showed good discriminatory capacity, although calibration was compromised due to mortality underestimation.</p>
      <p>We believe a multinational study in Brazil would be of paramount importance, with a greater number of patients, to propose and validate a score, since patients with IE in our country dramatically differ from those in North American or European countries, especially due to the high proportion of rheumatic valvopathy, group <italic>viridans</italic> streptococcal IE, longer delay time to diagnosis, and younger age.</p>
    </body>
    <back>
      <ack>
        <title>Acknowledgments</title>
        <p>We thank Dr. Carlos Rochitte, Editor-in-chief of <italic>Arquivos Brasileiros de Cardiologia</italic> , for the opportunity of debating infective endocarditis in this prestigious journal, and our colleagues at Instituto Nacional de Cardiologia for their partnership in the &#8220;endocarditis team&#8221; and in the <italic>Mestrado Profissional em Ci&#234;ncias Cardiovasculares</italic> .</p>
      </ack>
      <fn-group>
        <fn fn-type="other" id="fn1001">
          <p>
            <italic>Short Editorial related to the article: Analysis of Risk Scores to Predict Mortality in Patients Undergoing Cardiac Surgery for Endocarditis</italic>
          </p>
        </fn>
      </fn-group>
      <fn-group>
        <fn fn-type="financial-disclosure" id="fn2001">
          <p>Funding. Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado do Rio de Janeiro (FAPERJ; grant Jovem Cientista do Nosso Estado, # E26/202.782/2015).</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
